Back to Search Start Over

Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes

Authors :
Efficace, F
Mandelli, F
Avvisati, G
Cottone, F
Ferrara, F
Di Bona, E
Specchia, G
Breccia, M
Levis, A
Sica, Simona
Finizio, O
Kropp, Mg
Fioritoni, G
Cerqui, E
Vignetti, M
Amadori, S
Schlenk, Rf
Platzbecker, U
Lo Coco, F.
Sica, Simona (ORCID:0000-0003-2426-3465)
Efficace, F
Mandelli, F
Avvisati, G
Cottone, F
Ferrara, F
Di Bona, E
Specchia, G
Breccia, M
Levis, A
Sica, Simona
Finizio, O
Kropp, Mg
Fioritoni, G
Cerqui, E
Vignetti, M
Amadori, S
Schlenk, Rf
Platzbecker, U
Lo Coco, F.
Sica, Simona (ORCID:0000-0003-2426-3465)
Publication Year :
2014

Abstract

A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid (ATRA) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed, low- or intermediate-risk acute promyelocytic leukemia (APL). Here, we report health-related quality-of-life (HRQOL) results.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1105023752
Document Type :
Electronic Resource